Registry study on molecular subtypes of peripheral T-cell lymphoma
Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST Study)
This study is trying to learn more about different types of peripheral T-cell lymphoma in patients to help create better, more personalized treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 6 sites (Beijing and 5 other locations) |
| Trial ID | NCT05934864 on ClinicalTrials.gov |
What this trial studies
This is a multi-center, prospective registry study aimed at analyzing the clinical characteristics and prognosis of different molecular subtypes of peripheral T-cell lymphoma (PTCL). The study will collect data from patients diagnosed with PTCL through histopathology and gene sequencing, focusing on the heterogeneity of this subtype of non-Hodgkin lymphoma. By understanding these molecular subtypes, the study aims to inform future precision therapies for PTCL, potentially improving treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with peripheral T-cell lymphoma and whose molecular subtypes can be identified through gene sequencing.
Not a fit: Patients with a history of other malignancies (except certain skin cancers) or those with serious uncontrolled health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective, tailored treatments for patients with peripheral T-cell lymphoma.
How similar studies have performed: Other studies have shown promise in understanding molecular subtypes of lymphomas, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with peripheral T-cell lymphoma (PTCL) by histopathology from June 2023 to December 2026 and detected by gene sequencing (NGS) with different molecular subtypes. * Patients diagnosed with PTCL by histopathology from January 2023 to June 2023 and NGS detection can be performed if there is tumor tissue. * Informed consented * Age ≥ 18 years Exclusion Criteria: * History of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix prior to study treatment * Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease * Not able to comply to the protocol for mental or other unknown reasons * Patients with mentally disorders or other reasons unable to fully comply with the study protocol * Pregnant or lactation
Where this trial is running
Beijing and 5 other locations
- Peking University People's Hospital — Beijing, China (Recruiting)
- Henan Cancer Hospital — Henan, China (Recruiting)
- Affiliated Drum Tower Hospital, Medical School of Nanjing University — Nanjing, China (Recruiting)
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China — Shandong, China (Not_yet_recruiting)
- Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai, China (Recruiting)
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China — Sichuan, China (Recruiting)
Study contacts
- Study coordinator: Weili Zhao
- Email: zwl_trial@163.com
- Phone: +862164370045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.